There is a growing amount of evidence that brachytherapy’s role as a prostate cancer treatment modality should not be limited to low-risk cases, but should also include patients with higher risk disease.
The Journal of Clinical Oncology recently reported on an analysis of 42,765 patients with high-risk, clinically localized prostate cancer with complete prognostic data who were treated with either radical prostatectomy (RP), external beam radiotherapy (EBRT) combined with androgen deprivation (AD), or EBRT plus brachytherapy with or without AD.
The analysis showed, “There was no statistically significant difference in survival between RP and EBRT plus brachytherapy with or without AD. EBRT with AD was associated with lower survival”
“Too many men dealing with the challenges of high risk prostate cancer are still not aware of the different treatment options that are available to them,” said Isoray Vice President Michael Krachon. “The time for that to change is long past due. Many of these men could be effectively treated with brachytherapy — in an outpatient setting, at lower overall cost and impact to their long-term quality of life.”
Isoray’s proprietary Cesium-131 isotope is the next generation of brachytherapy. With a shorter half-life and higher energy than other commonly used radioisotopes, Cesium-131 by Isoray has been shown to be a highly effective cancer treatment when planned appropriately. Treatment with Cesium-131 results in patients making a quick recovery from their treatment and then experiencing a speedy return to their baseline urinary function.
It is time for those treating prostate cancer to take another look at brachytherapy. To arrange a call or meeting contact customerservice@isoray.com .
